Other key agents in this class are dulaglutide and the novel dual GIP/GLP-1 receptor agonist, tirzepatide [16,17,18,19]
Protege al organismo de las toxinas ambientales
For instance, a user might describe their experience with a side effect, like a yeast infection, and other people who read it might wonder if they could have the same issue
Retatrutide, which has not yet completed clinical trials, is an experimental injection developed by the US drugmaker Eli Lilly that targets three gut hormones: GLP-1, GIP and glucagon
Ismail AM, Hamed AH, Saso S, Thabet HH
Retrieved 15 May 2025